Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | Update on venetoclax combination trials for elderly AML from ASH 2017

Marina Konopleva • 9 Dec 2017
ASH 2017
Acute Myeloid Leukemia Azacitidine Cobimetinib Decitabine Idasanutlin Venetoclax

There were impressive updates on venetoclax combination studies for elderly acute myeloid leukemia (AML) that are progressing at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. Speaking from the meeting, Marina Konopleva, MD, PhD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the studies, including the combination of venetoclax with azacitidine/decitabine (NCT02203773), low-dose cytarabine (NCT02287233), and cobimetinib and idasanutlin (NCT02670044). Dr Konopleva explains the exciting data so far, highlighting the utility of these new treatments, which are much needed for elderly AML, where treatment options are very limited.

More from Marina Konopleva

2:41
Advancements in AML: an update from ASH 2023
Marina Konopleva • 8 Dec 2023
1:36
The synergetic mechanism of pivekimab sunirine and venetoclax and its potential for treating AML
Marina Konopleva • 8 Dec 2023
1:03
10-day ASTX727 (decitabine/cedazuridine) with venetoclax in the treatment of R/R AML
Marina Konopleva • 8 Dec 2023
1:17
Targeting mitochondrial metabolism to eradicate MRD in AML
Marina Konopleva • 8 Dec 2023

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals